Mechanisms of epileptogenesis and potential treatment targets

Asla Pitkänen1, Katarzyna Lukasiuk

  • 1Department of Neurobiology, A I Virtanen Institute for Molecular Sciences, University of Eastern Finland, and Department of Neurology, Kuopio University Hospital, Kuopio, Finland. asla.pitkanen@uef.fi

The Lancet. Neurology
|January 25, 2011
PubMed

Insights

Preventing epileptogenesis after brain trauma is challenging but achievable. Experimental studies show targeting molecular pathways can favorably modify seizure development, offering hope for new antiepileptogenesis treatments.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Epileptogenesis following brain trauma remains a significant unmet medical challenge.
  • Molecular profiling reveals key mechanisms in ictogenic network formation, including plasticity, cell death, and inflammation.
  • Understanding these pathways is crucial for developing targeted interventions.

Purpose of the Study:

  • To review current strategies for preventing epileptogenesis after brain injury.
  • To explore the potential of targeting molecular mechanisms involved in seizure development.
  • To assess the efficacy of various therapeutic approaches in preclinical models.

Main Methods:

  • Review of recent molecular profiling studies and preclinical research.
  • Analysis of therapeutic interventions targeting identified molecular pathways.
  • Evaluation of experimental data from animal models of post-traumatic epilepsy.

Main Results:

  • Favorable effects observed with immunosuppressants, anti-leukocyte adhesion antibodies, and gene therapy.
  • Pharmacological neurostimulation and early administration of antiepileptic drugs show promise.
  • Experimental studies demonstrate that epileptogenesis can be favorably modified.

Conclusions:

  • Targeting molecular mechanisms offers a viable strategy for antiepileptogenesis.
  • Further research is needed to optimize treatment timing and specificity.
  • Antiepileptogenesis represents a promising, albeit complex, therapeutic goal.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...